• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Treace Medical Concepts Inc.

    5/14/26 4:13:01 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care
    Get the next $TMCI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    TREACE MEDICAL CONCEPTS, INC.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    89455T109

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    89455T109


    1Names of Reporting Persons

    BANK OF AMERICA CORP /DE/
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,533,774.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,533,774.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,533,774.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.5 %
    12Type of Reporting Person (See Instructions)

    HC

    Comment for Type of Reporting Person:  The beneficial ownership calculation relies on the 64,590,503 outstanding shares disclosed in the Form 10-K by the issuer on February 27, 2026, which reports share totals as of February 20, 2026.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    TREACE MEDICAL CONCEPTS, INC.
    (b)Address of issuer's principal executive offices:

    100 PALMETTO PARK PLACE, PONTE VEDRA, FLORIDA, 32081.
    Item 2. 
    (a)Name of person filing:

    BANK OF AMERICA CORP /DE/
    (b)Address or principal business office or, if none, residence:

    100 N TRYON ST CHARLOTTE, NC 28255
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP Number(s):

    89455T109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    3,533,774.00
    (b)Percent of class:

    5.5%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0.00

     (ii) Shared power to vote or to direct the vote:

    3,533,774.00

     (iii) Sole power to dispose or to direct the disposition of:

    0.00

     (iv) Shared power to dispose or to direct the disposition of:

    3,533,774.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    This statement on Schedule 13G is being filed by Bank of America Corporation on behalf of itself and its wholly owned subsidiaries BofA Securities, Inc., a broker dealer registered under section 15 of the Act (15 U.S.C. 78o); Bank of America N.A., a bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); and Merrill Lynch International, a non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J).
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BANK OF AMERICA CORP /DE/
     
    Signature:/s/ Monica Yako
    Name/Title:Authorized Signatory
    Date:05/14/2026
    Get the next $TMCI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TMCI

    DatePrice TargetRatingAnalyst
    11/7/2025$5.00Neutral → Underweight
    Analyst
    11/7/2025Buy → Neutral
    BTIG Research
    2/4/2025$16.00Neutral → Buy
    BTIG Research
    12/31/2024$14.50Buy
    Lake Street
    12/17/2024$8.00Neutral
    Analyst
    5/16/2024$16.00 → $6.50Buy → Neutral
    UBS
    5/8/2024$15.00 → $5.50Overweight → Equal-Weight
    Morgan Stanley
    5/8/2024$17.00 → $7.00Buy → Hold
    Truist
    More analyst ratings

    $TMCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Treace John T. bought $177,915 worth of shares (50,000 units at $3.56), increasing direct ownership by 0.69% to 7,323,833 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    6/1/26 4:38:10 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Treace John T. bought $340,589 worth of shares (115,520 units at $2.95), increasing direct ownership by 2% to 7,273,833 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    5/28/26 4:33:12 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Director Jain Deepti was granted 30,000 shares, increasing direct ownership by 43% to 100,243 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    5/19/26 9:00:06 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Treace Medical Concepts Reports First Quarter 2026 Financial Results

    PONTE VEDRA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Generated revenue of $47.2 million in first quarter 2026 compared to $52.6 million in the same period in 2025. Reported first quarter 2026 net loss of $(18.0) million and adjusted EBITDA of $(5.5) million in the first quarter 2026.Cash, cash equivalents, and marketable securities totaled $51.9 million as of March 31, 2026, representing an increase

    5/8/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace to Report First Quarter 2026 Financial Results on May 8, 2026

    PONTE VEDRA, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the first quarter 2026 before the start of trading on Friday, May 8, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and ar

    4/24/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Announces First Surgical Cases with the SuperBite™ Compression Screw System

    PONTE VEDRA, Fla., April 07, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the successful completion of the first cases utilizing its SuperBite™ Compression Screw System. SuperBite™ screws are engineered to deliver advanced compression through a variable thread pitch and optimized headless design, with its self-drilling and countersinking features enabling rapid screw insertion. The screw implants also incorporate a beveled head design with smoothed edges, making them ideal for both minimally inva

    4/7/26 9:04:29 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Treace Medical Concepts downgraded by Analyst with a new price target

    Analyst downgraded Treace Medical Concepts from Neutral to Underweight and set a new price target of $5.00

    11/7/25 8:29:21 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts downgraded by BTIG Research

    BTIG Research downgraded Treace Medical Concepts from Buy to Neutral

    11/7/25 8:29:10 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts upgraded by BTIG Research with a new price target

    BTIG Research upgraded Treace Medical Concepts from Neutral to Buy and set a new price target of $16.00

    2/4/25 7:10:07 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Treace John T. bought $177,915 worth of shares (50,000 units at $3.56), increasing direct ownership by 0.69% to 7,323,833 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    6/1/26 4:38:10 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Treace John T. bought $340,589 worth of shares (115,520 units at $2.95), increasing direct ownership by 2% to 7,273,833 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    5/28/26 4:33:12 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Treace John T. bought $375,505 worth of shares (153,763 units at $2.44), increasing direct ownership by 2% to 7,158,313 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    5/14/26 5:33:05 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    SEC Filings

    View All

    Treace Medical Concepts Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

    5/20/26 5:30:15 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Treace Medical Concepts Inc.

    SCHEDULE 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    5/15/26 11:19:26 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Treace Medical Concepts Inc.

    SCHEDULE 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    5/14/26 4:13:01 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Leadership Updates

    Live Leadership Updates

    View All

    Treace Appoints Guy Guglielmino as Chief Commercial Officer

    PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace's commercial efforts and play a pivotal role in driving the Company's next phase of rapid innovation, strategic product commercialization, and growth. "I am thrilled to welcome Guy to the Treace team," said John T. Treace, CEO, Founder and B

    12/2/24 4:15:00 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing

    PONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this new position, Mr. Minnich will lead all aspects of Treace's marketing efforts, with a focus on expanding the Company's physician outreach, patient awareness and market penetration efforts.  "I am delighted to welcome Nathan to the Treace team," said John T. Treace, CEO, Fou

    8/21/23 7:00:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Appoints Julie Dewey as Chief Communications and Investor Relations Officer

    PONTE VEDRA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that Julie Dewey will join the Company as Chief Communications and Investor Relations Officer, effective July 17, 2023. In this new position, Ms. Dewey will lead all aspects of Treace's corporate communications and investor relations engagement, with a focus on expanding the company's outreach with the investment community and broadening the Company's relationships wit

    7/12/23 4:15:00 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Financials

    Live finance-specific insights

    View All

    Treace Medical Concepts Reports First Quarter 2026 Financial Results

    PONTE VEDRA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Generated revenue of $47.2 million in first quarter 2026 compared to $52.6 million in the same period in 2025. Reported first quarter 2026 net loss of $(18.0) million and adjusted EBITDA of $(5.5) million in the first quarter 2026.Cash, cash equivalents, and marketable securities totaled $51.9 million as of March 31, 2026, representing an increase

    5/8/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace to Report First Quarter 2026 Financial Results on May 8, 2026

    PONTE VEDRA, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the first quarter 2026 before the start of trading on Friday, May 8, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and ar

    4/24/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results

    PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025. Recent Highlights Generated revenue of $62.5 million in fourth quarter 2025 and revenue of $212.7 million for the full-year 2025, an increase of 2% compared to the prior year.Reported fourth quarter 2025 net loss of $(9.4) million and adjusted EBITDA of $6.2 million in the fourth quarter 2025. Reported full-year 2025 net loss of $(59.0) million c

    2/27/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Treace Medical Concepts Inc.

    SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    11/14/24 3:38:23 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Treace Medical Concepts Inc.

    SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    11/12/24 6:01:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Treace Medical Concepts Inc.

    SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    11/8/24 3:44:13 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care